Glycan-interacting compounds
The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
1. A method of treating cancer comprising administering a glycan-interacting antibody to a subject in need thereof, said glycan-interacting antibody comprising a heavy chain variable domain (VH) with the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain (VL) with the amino acid sequence of SEQ ID NO: 2, wherein said cancer comprises cells having an antigen bound by said antibody.
2. The method of claim 1 , wherein said glycan-interacting antibody targets a cancer-related antigen.
3. The method of claim 2 , wherein said cancer-related antigen comprises at least one glycan, said at least one glycan comprising at least one sialic acid residue.
4. The method of claim 3 , wherein said at least one glycan comprises at least one of Neu5Gcα2,6GalNAc; Neu5Gcα2,6Galβ1,4GlcNAc; Neu5Gcα2,6Galβ1,4Glc; and Neu5Gcα2,6Gal.
5. The method of claim 3 , wherein said at least one glycan comprises a 9-O-acetylated glycan.
6. The method of claim 5 , wherein said 9-O-acetylated glycan is one of Neu5Gc9Acα2,6Galβ1,4GlcNAc; Neu5Gc9Acα2,6GalNAc; Neu5Gc9Acα2,6Gal; and Neu5Gc9Acα2,6Galβ1,4Glc.
7. A method of delivering a payload to a cell, the method comprising contacting said cell with a glycan-interacting antibody, said glycan-interacting antibody comprising a heavy chain variable domain (VH) with the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain (VL) with the amino acid sequence of SEQ ID NO: 2, wherein said payload is attached to said glycan-interacting antibody and wherein said cell has an antigen bound by said antibody.
8. The method of claim 7 , wherein the payload is conjugated to the glycan-interacting antibody prior to contacting said cell.
9. The method of claim 8 , wherein the payload is conjugated to the glycan-interacting antibody using a linker.
10. The method of claim 9 , wherein said payload is a therapeutic agent.
11. The method of claim 10 , wherein the therapeutic agent comprises at least one of a cytotoxin, a radioactive ion, and a chemotherapeutic agent.
12. The method of claim 8 , wherein the payload is a detectable agent.
13. The method of claim 12 , wherein the detectable agent is an enzyme.
14. The method of claim 12 , wherein the detectable agent is fluorescent.
15. The method of claim 7 , wherein said payload is attached to said glycan-interacting antibody by a secondary antibody.
16. The method of claim 15 , wherein the payload is a detectable agent.
17. The method of claim 16 , wherein the detectable agent is an enzyme.
18. The method of claim 16 , wherein the detectable agent is fluorescent.